Nasdaq · Healthcare
CERUS CORP (CERS)
As-reported financials and recent SEC filings for CERUS CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$233.8M
Net income
$-15.6M
Net margin
-6.7%
Diluted EPS
$-0.08
ROE
-24.1%
P/E (TTM)
—
Market cap
$585.1M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $233.8M | $201.3M | $186.8M | $188.3M | $159.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-8.7M | $-14.2M | $-30.1M | $-34.1M | $-48.9M |
| Net income | $-15.6M | $-20.9M | $-37.5M | $-42.8M | $-54.4M |
| Diluted EPS | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-11
View on EDGAR →1442026-06-09
View on EDGAR →8-K2026-06-08
View on EDGAR →8-K2026-06-03
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on CERS
Search CERUS CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.